MTOR and breast cancer: Briefly, we took advantage of our previously published transcriptome, proteome, and phosphoproteome dataset of breast cancer cells upon treatment with metformin30, whose molecular targets (the mammalian target of rapamycin, mTOR, and the AMP-activated protein kinase, AMPK) and phenotypic impact are well characterized31–37 (Fig. 2C).